HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

SUBCUTANEOUS METHOTREXATE

Otrexup®, Rasuvo®, RediTrex™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

	claimer: Prior Authorization question				eral and State notice requirements	
וכוט	ciainier. Frior Authorization request to	in accord	iance w	itii i eue	rai and State Hotice requirements.	
Date:		Member Name:		ID#:		
DOB:		Gender:	er: Phys		ician:	
Office Phone:		Office Fax:		Offic	ce Contact:	
Hei	ght/Weight:					
pre rea	ember must try formulary preferred dru Eferred products has not been successfu Ison for failure. Reasons for failure mu Eferred: ☐ RediTrex® n-preferred: ☐ Otrexup®, ☐ Rasuvo™	ul, you must submit which preferre	d produ	cts have	e been tried, dates of treatment, and	
Dos	sing/Frequency:					
	If the request is	s for reauthorization, proceed to	o reaut	horizat	ion section	
	Question	ns	Yes	No	Comments/Notes	
1.	Question Has the member been diagnosed warthritis or polyarticular juvenile in recalcitrant, disabling psoriasis?	with severe, active rheumatoid	Yes	No	Comments/Notes	
	Has the member been diagnosed varthritis or polyarticular juvenile id	with severe, active rheumatoid diopathic arthritis or severe,			Comments/Notes Please provide documentation	
	Has the member been diagnosed warthritis or polyarticular juvenile ic recalcitrant, disabling psoriasis?	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate?				
2.	Has the member been diagnosed of arthritis or polyarticular juvenile in recalcitrant, disabling psoriasis? Has the member had a trial and far has the member had a trial and far	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into			Please provide documentation	
2.	Has the member been diagnosed of arthritis or polyarticular juvenile in recalcitrant, disabling psoriasis? Has the member had a trial and far has the member had a trial and far intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into			Please provide documentation Please provide documentation	
2.	Has the member been diagnosed of arthritis or polyarticular juvenile is recalcitrant, disabling psoriasis? Has the member had a trial and fa Has the member had a trial and fa intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to environmental factors?	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into p mechanical, physical, or REAUTHORIZATION of therapy?			Please provide documentation Please provide documentation	
2. 3. 4.	Has the member been diagnosed of arthritis or polyarticular juvenile ic recalcitrant, disabling psoriasis? Has the member had a trial and far Has the member had a trial and far intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to environmental factors?	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into p mechanical, physical, or REAUTHORIZATION of therapy?			Please provide documentation Please provide documentation	
 2. 3. 4. 	Has the member been diagnosed of arthritis or polyarticular juvenile is recalcitrant, disabling psoriasis? Has the member had a trial and far has the member had a trial and far intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to environmental factors? Is the request for reauthorization of the trial and far trial and far intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to environmental factors?	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into p mechanical, physical, or REAUTHORIZATION of therapy? e-evaluated within the past 6			Please provide documentation Please provide documentation	
2. 3. 4. 1. 2.	Has the member been diagnosed of arthritis or polyarticular juvenile is recalcitrant, disabling psoriasis? Has the member had a trial and far has the member had a trial and far intramuscular methotrexate? Is the member unable to draw up a syringe or self-administer, due to environmental factors? Is the request for reauthorization of the Has the member's therapy been remonths? Has the therapy shown to be toler	with severe, active rheumatoid diopathic arthritis or severe, ilure with oral methotrexate? ilure, with subcutaneous or methotrexate from a vial into p mechanical, physical, or REAUTHORIZATION of therapy? e-evaluated within the past 6 able and effective with an			Please provide documentation Please provide documentation Please provide documentation	

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.
name of treatment, reason for failure, treatment dates, etc.
Additional information:
Physician's Signature:

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-HU-070 Origination Date: 01/01/2022 Reviewed/Revised Date: 07/31/2023 Next Review Date: 07/31/2024 Current Effective Date: 10/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.